Zevra Therapeutics (ZVRA) Cash from Investing Activities (2014 - 2026)

Zevra Therapeutics' Cash from Investing Activities history runs 13 years deep, the most recent figure standing at $79.6 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 655.25% year-over-year to $79.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.2 million (up 430.16% YoY) and the FY2025 annual result came in at $18.1 million, up 181.8% from the prior year.
• Cash from Investing Activities was $79.6 million for Q1 2026 at Zevra Therapeutics, up from $227000.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $79.6 million in Q1 2026 and bottomed at -$44.5 million in Q3 2023.
• A 5-year average of $1.3 million and a median of -$63000.0 in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 40739.51% — and 2023, when it jumped 16901.59%.
• Zevra Therapeutics' Cash from Investing Activities stood at -$63000.0 in 2022, then soared by 16901.59% to $10.6 million in 2023, then sank by 151.69% to -$5.5 million in 2024, then soared by 104.15% to $227000.0 in 2025, then jumped by 34974.01% to $79.6 million in 2026.
• Business Quant data shows ZVRA's Cash from Investing Activities at $79.6 million in Q1 2026, $227000.0 in Q4 2025, and -$4.6 million in Q3 2025.